Moderna's CFO, Jamey Mock, discusses capital allocation in big pharma, addressing the challenges of choosing projects amidst drug development uncertainty. Moderna's stock, $MRNA, experienced a 9% increase in value on high volume trading. Layoffs at Moderna hint at the end of the COVID vaccine boom, with revenue expected to drop from $19B in 2022 to $4B in 2024. Despite this, the company's strong pipeline raises hopes for a stock rebound. Moderna executive hints at potential partnerships and project financing to fund pipeline programs beyond 2026.
MODERNA EXEC SAYS CO COULD CONSIDER PARTNERSHIPS AND PROJECT FINANCING AS OPTIONS TO FUND PIPELINE PROGRAMS BEYOND 2026 -BARCLAYS CONF.
Consider that morons were buying $MRNA stock today....unreal. https://t.co/4xRFTZkJw6
We became bear on $mrna at 70. Stock now clears 112. Amazing ripper. https://t.co/fvKd7XWwnT
💉Pandemic Profits Pivot: Moderna $MRNA layoffs signal the end of the COVID vaccine boom. Revenue predicted to plummet from $19B in 2022 to $4B in 2024. But with a strong pipeline, could a stock rebound be on the horizon? 🤔@jonnajarian and @PeteNajarian discuss on Rebel's Edge… https://t.co/MLnMDsWg4S
$MRNA up 9% on very high volume, momentum unwind?
Moderna's CFO joins to Odd Lots podcast to discuss how capital is really allocated in big pharma https://t.co/v0rXHCRwb2
NEW ODD LOTS: A new area for us. @tracyalloway and I talked to Moderna CFO Jamey Mock on the subject of capital allocation in pharma. How do you choose what projects to invest in next, given the extreme uncertainty of drug development? $MRNA https://t.co/vXiShcOzxI
Moderna's CFO on How to Allocate Capital in Big Pharma https://t.co/r2e4xxSwMu